Full text is available at the source.
Abstract
A clinically usable framework is proposed to differentiate receptor architecture and metabolic potency from the maturity of outcome evidence for incretin-based therapies.
- The framework aims to clarify the relationship between receptor design and the effectiveness of incretin therapies.
- It addresses the varying levels of evidence related to patient outcomes associated with these therapies.
- Separation of these elements could enhance the understanding of how different therapies may perform in clinical settings.
Simplified